about
Effect of simvastatin and atorvastatin on serum vitamin d and bone mineral density in hypercholesterolemic patients: a cross-sectional study.Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of Clostridium difficile.In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Association of healthcare exposure with acquisition of different Clostridium difficile strain types in patients with recurrent infection or colonization after clinical resolution of initial infection.An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomesPhysical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile InfectionAssessment of In Vivo Efficacy of Eravacycline against Enterobacteriaceae Exhibiting Various Resistance Mechanisms: A Dose-Ranging Study and PK/PD Analysis.Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.Development of a Novel Pharmaceutical Formula of Nanoparticle Lipid Carriers of Gentamicin/α-Tocopherol and In Vivo Assessment of the Antioxidant Protective Effect of α-Tocopherol in Gentamicin-Induced NephrotoxicityAntibiotic penetration into bone and joints: An updated reviewComparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelinesAntibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: A retrospective case-control study
P50
Q34100680-57C4596D-1F68-4AD5-AE51-2CCEABD855B3Q36161086-329EB0D3-27D3-4640-803B-1B1918AFE627Q36439072-1172D0EB-9896-4844-9770-37987F0CA7F3Q36793747-4C1F1273-B1AA-4FE1-BDB4-B876EC9E2744Q37119959-A5A63BEA-3F79-4AC2-83DC-E445849B00B7Q37120165-AA3643D4-0178-49D3-91DA-00C205B7127CQ37287648-71517480-188F-4BFB-9094-12686E0C4D21Q38286351-D7182819-3506-4576-BD61-DDC4E677C4D6Q38705190-BD0D4F78-1E58-46E8-ABA1-87154C4C68CAQ38844052-93D7EA8E-15E4-4F72-B7F7-FAF7D71612CAQ40398288-4CC3463A-F98B-4F23-B2A1-5D32A4061C64Q40398295-02D36DDF-CB10-4C15-8385-A5ED42B56E40Q40466100-59AA5B04-DBE2-4374-ADE3-0BD8015839CEQ40900580-BAFE041E-68AB-478C-A5ED-A9088D009660Q41174780-9DDCCDEA-1CE0-4C05-8A78-9DBEB759C92EQ41423849-04AB8603-DD06-4133-B8D1-3AEF4DF142EEQ50080413-71E2D70B-9405-4477-9A55-BE89334107DAQ53749025-C2B848BA-AD60-4FB4-B5A4-5DA3336E2943Q91490676-45BAC179-FB1F-4A72-8083-BAD47C9EE964Q91649601-3B54D709-5B87-4ACA-A0BA-ED00366B16EFQ92718331-73FDCAAC-9BB1-41AA-8865-1D08A4EEF8A6Q93121566-434A5E2E-42D4-4940-9189-2CB0C4111F73
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Abrar K Thabit
@ast
Abrar K Thabit
@en
Abrar K Thabit
@es
Abrar K Thabit
@nl
type
label
Abrar K Thabit
@ast
Abrar K Thabit
@en
Abrar K Thabit
@es
Abrar K Thabit
@nl
prefLabel
Abrar K Thabit
@ast
Abrar K Thabit
@en
Abrar K Thabit
@es
Abrar K Thabit
@nl
P106
P1153
55259827800
56369329200
P31
P496
0000-0002-0369-9094